KR20240132100A - 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 - Google Patents

키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 Download PDF

Info

Publication number
KR20240132100A
KR20240132100A KR1020247027659A KR20247027659A KR20240132100A KR 20240132100 A KR20240132100 A KR 20240132100A KR 1020247027659 A KR1020247027659 A KR 1020247027659A KR 20247027659 A KR20247027659 A KR 20247027659A KR 20240132100 A KR20240132100 A KR 20240132100A
Authority
KR
South Korea
Prior art keywords
cell
car
cells
macrophages
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027659A
Other languages
English (en)
Korean (ko)
Inventor
자르 길
마이클 클리친스키
칼 에이치. 준
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Publication of KR20240132100A publication Critical patent/KR20240132100A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A61K39/4614—
    • A61K39/4615—
    • A61K39/4631—
    • A61K39/464406—
    • A61K39/464412—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247027659A 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 Pending KR20240132100A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562197675P 2015-07-28 2015-07-28
US62/197,675 2015-07-28
KR1020187005871A KR102697827B1 (ko) 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
PCT/US2016/044440 WO2017019848A1 (en) 2015-07-28 2016-07-28 Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005871A Division KR102697827B1 (ko) 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20240132100A true KR20240132100A (ko) 2024-09-02

Family

ID=57885035

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247027659A Pending KR20240132100A (ko) 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
KR1020187005871A Active KR102697827B1 (ko) 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187005871A Active KR102697827B1 (ko) 2015-07-28 2016-07-28 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도

Country Status (13)

Country Link
US (13) US11034749B2 (https=)
EP (1) EP3328402A4 (https=)
JP (4) JP7032304B2 (https=)
KR (2) KR20240132100A (https=)
CN (3) CN108025024B (https=)
AU (3) AU2016298229B2 (https=)
BR (1) BR112018001858B1 (https=)
HK (1) HK1256141A1 (https=)
IL (4) IL315940A (https=)
MX (2) MX393707B (https=)
RU (1) RU2766690C2 (https=)
WO (1) WO2017019848A1 (https=)
ZA (1) ZA201800611B (https=)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
RU2766690C2 (ru) * 2015-07-28 2022-03-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CN108243607A (zh) 2015-09-09 2018-07-03 西雅图儿童医院（Dba西雅图儿童研究所） 用于免疫疗法的巨噬细胞的遗传工程
KR20180054600A (ko) * 2015-10-13 2018-05-24 브라이엄 영 유니버시티 면역치료에서의 대식세포 키메라 항원 수용체(moto-car)
US10875919B2 (en) * 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP4089116A1 (en) 2016-09-27 2022-11-16 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CN107286246B (zh) * 2016-12-28 2019-12-17 时力生物科技（北京）有限公司 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
JP7164598B2 (ja) * 2017-05-17 2022-11-01 サンダー・バイオテック・インコーポレイテッド トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3688032B1 (en) 2017-09-26 2025-11-05 Cero Therapeutics Holdings, Inc. Chimeric engulfment receptor molecules and methods of use
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
MX2020006843A (es) * 2017-12-27 2020-09-03 Takeda Pharmaceuticals Co Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
KR20200120917A (ko) * 2018-02-02 2020-10-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 키메라 항원 수용체를 발현하는 변형된 단핵구/대식세포/수지상 세포 및 단백질 응집체와 연관이 있는 질환 및 장애에서의 용도
CN112004829A (zh) * 2018-03-12 2020-11-27 南克维斯特公司 Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
RU2020135106A (ru) * 2018-03-28 2022-04-29 Серо Терапьютикс, Инк. Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7444781B2 (ja) * 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
US20210015865A1 (en) * 2018-03-28 2021-01-21 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
AU2019304290A1 (en) 2018-07-19 2021-02-04 Oncohost Ltd IL-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
EP3844500A4 (en) 2018-08-27 2022-05-11 NantBio, Inc. RP182 COMPOSITIONS AND METHODS
BR112021003640A2 (pt) 2018-08-31 2021-05-18 Noile-Immune Biotech, Inc. célula t, medicamento, vetor de expressão, e, métodos para produzir uma célula de t car e para tratar câncer
US20220119476A1 (en) * 2018-08-31 2022-04-21 The Trustees Of The University Of Pennsylvania Activation of Antigen Presenting Cells and Methods for Using the Same
CN111004781A (zh) * 2018-10-08 2020-04-14 南加利福尼亚大学 长期扩增粒细胞-巨噬细胞祖细胞的方法及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3917967A4 (en) * 2019-02-01 2023-02-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Microenvironment sensors to regulate engineered gene expression
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12018061B2 (en) * 2019-03-08 2024-06-25 St Phi Therapeutics Co., Ltd. Chimeric endocytic receptors and method of use thereof
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CA3135531A1 (en) * 2019-04-30 2020-11-05 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
US20220162644A1 (en) * 2019-05-29 2022-05-26 Orbis Health Solutions, Llc Delivery vectors and particles for expressing chimeric receptors and methods of using the same
EP3991746A4 (en) 2019-06-26 2023-08-09 Takeda Pharmaceutical Company Limited TRANSFECTION METHOD
KR20220063156A (ko) * 2019-07-19 2022-05-17 인스티튜트 구스타브 루시 암세포 요법을 위한 p21 발현 단핵구
CN118165120A (zh) * 2019-07-22 2024-06-11 南京助天中科科技发展有限公司 一种嵌合抗原受体及其应用
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
JP7831937B2 (ja) 2019-09-03 2026-03-17 クリエイト・メディシンズ，インコーポレーテッド ゲノム組込みのための方法および組成物
CN114502781B (zh) 2019-09-20 2025-06-17 纳维再生科技股份有限公司 个人化癌症免疫治疗
KR102498546B1 (ko) * 2019-09-27 2023-02-09 한국생명공학연구원 항체를 분비하는 대식세포의 제조방법 및 이를 이용한 항암치료 기술
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
BR112022011339A2 (pt) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc Composições de células terapêuticas e métodos para fabricação e usos das mesmas
CN110954701B (zh) * 2019-12-18 2023-07-21 重庆医科大学 一种肝纤维化或肝硬化的诊断试剂盒
CN113106067B (zh) * 2020-01-10 2024-06-21 南京大学 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用
CN115003701A (zh) * 2020-01-19 2022-09-02 北京卡替医疗技术有限公司 一种提升免疫细胞功能的增强受体
EP4105240A4 (en) * 2020-02-13 2024-05-29 Sichuan University Chimeric antigen receptor and use thereof
US12606635B2 (en) * 2020-03-12 2026-04-21 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
CA3177330A1 (en) * 2020-05-05 2021-11-11 Aro Biotherapeutics Company Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same
EP3915576A1 (en) * 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
CN115867294A (zh) * 2020-06-04 2023-03-28 凯瑞斯马治疗公司 嵌合抗原受体的新型构建体
CN111840324B (zh) * 2020-06-16 2023-05-12 上海市第一人民医院 应用于骨肉瘤细胞成像或治疗的Au DENPs-巨噬细胞复合物
CA3187138A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells
CN111925448B (zh) * 2020-08-03 2022-06-21 山东大学 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用
GB202014920D0 (en) 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases
CA3193508A1 (en) * 2020-09-23 2022-03-31 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CN112830974B (zh) * 2021-01-08 2022-07-26 深圳市珈钰生物科技有限公司 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用
CN116802300A (zh) * 2021-01-15 2023-09-22 国立大学法人东海国立大学机构 嵌合靶因子受体
US20240066059A1 (en) * 2021-03-03 2024-02-29 Seoul National University R&Db Foundation Method for producing chimeric antigen receptor-macrophages and use of same cells
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022203226A1 (ko) * 2021-03-22 2022-09-29 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220131801A (ko) 2021-03-22 2022-09-29 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220132401A (ko) 2021-03-23 2022-09-30 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
WO2022203227A1 (ko) * 2021-03-23 2022-09-29 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
WO2022211376A1 (ko) * 2021-04-01 2022-10-06 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220136876A (ko) 2021-04-01 2022-10-11 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
WO2022215920A1 (ko) * 2021-04-06 2022-10-13 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
CN114934071B (zh) * 2021-04-30 2023-10-17 四川大学华西医院 一种表达免疫调节因子的car载体及其应用
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
EP4340871A4 (en) * 2021-05-19 2025-05-21 University of Southern California Chimeric antigen receptor-modified granulocyte macrophage precursors for cancer immunotherapy
CN113321743B (zh) * 2021-07-02 2022-10-21 海南精准医疗科技有限公司 一种靶向赖氨酰氧化酶1的嵌合抗原受体及其用途
KR20230089462A (ko) * 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20230089464A (ko) * 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
CN114410588B (zh) * 2022-01-29 2022-11-04 西安电子科技大学 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用
EP4504244A1 (en) 2022-04-07 2025-02-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
CA3247582A1 (en) * 2022-04-18 2023-10-26 Wisconsin Alumni Research Foundation COMBINATIONAL IMMUNOTHERAPIES INVOLVING CAR-M, CAR-NK, CAR-EOS AND CAR-N CELLS
CN118178626A (zh) * 2022-04-29 2024-06-14 苏州易慕峰生物科技有限公司 抗原递呈细胞及car-t细胞联合在抗肿瘤中的应用
GB202208605D0 (en) 2022-06-13 2022-07-27 Unikum Therapeutics Aps Engineered immune cells
EP4570905A1 (en) * 2022-08-09 2025-06-18 Agc Inc. Method for producing proliferative macrophage-like cells (pmac)
JP2025542299A (ja) * 2022-12-21 2025-12-25 ウニヴェルズィテート チューリッヒ マクロファージを極性化するための方法
CN115957335B (zh) * 2023-01-03 2024-05-28 华中科技大学同济医学院附属协和医院 基于嵌合抗原受体修饰的单核细胞外囊泡类似物、制备方法及应用
CN116218786B (zh) * 2023-03-09 2024-01-23 山东大学齐鲁医院 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用
CN116380580A (zh) * 2023-03-15 2023-07-04 中国人民解放军空军军医大学 一种血浆检测前处理方法
WO2024210160A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited Conjugation complex
EP4483866A1 (en) 2023-06-28 2025-01-01 Makrolife Biotech GmbH Pharmaceutical compositions for the treatment or prevention of cancer
CN120005830A (zh) * 2023-11-06 2025-05-16 复星凯瑞(上海)生物科技有限公司 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用
GB202318553D0 (en) 2023-12-05 2024-01-17 Unikum Therapeutics Aps Engineered plasmacytoid dendritic cells
CN118059217B (zh) * 2023-12-20 2025-02-28 西安电子科技大学 一种表观遗传药物联合过继单核/巨噬细胞免疫治疗在制备肿瘤疾病生物药品中的应用
CN118206664A (zh) * 2024-02-04 2024-06-18 中国科学院杭州医学研究所 原位生成多功能嵌合抗原受体巨噬细胞的方法及其在免疫治疗中的应用
CN118685362A (zh) * 2024-05-15 2024-09-24 西安电子科技大学 一种癌环境响应型的过继单核或巨噬细胞免疫治疗生物制品及其在抗肿瘤中的应用
CN121488047A (zh) * 2024-07-15 2026-02-06 南京元迈细胞生物科技有限公司 腺病毒载体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334764A (en) 1966-10-25 1967-08-08 John P Fouser Infant nurser
US20040053837A1 (en) * 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
CA2476452A1 (en) 2002-02-15 2003-08-28 Zycos Inc. Electroporation methods for introducing bioactive agents into cells
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
RU2433825C2 (ru) 2004-12-06 2011-11-20 Медисинова, Инк. Способ лечения невропатической боли и связанных с ней синдромов
JP4604892B2 (ja) 2005-07-15 2011-01-05 船井電機株式会社 情報記録／再生装置
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
WO2011106521A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of macrophage activation
AU2011239569B2 (en) * 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013051718A1 (ja) * 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
JP6021617B2 (ja) 2012-12-05 2016-11-09 カンタツ株式会社 撮像レンズ
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
TW201446794A (zh) * 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
WO2014153114A1 (en) 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
DE102013215794A1 (de) 2013-08-09 2015-02-12 Krones Ag Vorrichtung und Verfahren zum Ausrichten von unrunden Behältern
GB201315036D0 (en) 2013-08-22 2013-10-02 Renishaw Plc Apparatus and method for building objects by selective solidification of powder material
WO2016033331A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016149254A1 (en) 2015-03-17 2016-09-22 Chimera Bioengineering, Inc. Smart car devices, de car polypeptides, side cars and uses thereof
WO2016176651A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
US20170216354A1 (en) 2015-06-12 2017-08-03 Batu Biologics, Inc. Clinically useful non-antigen pulsed dendritic cells
RU2766690C2 (ru) * 2015-07-28 2022-03-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
KR20180054600A (ko) 2015-10-13 2018-05-24 브라이엄 영 유니버시티 면역치료에서의 대식세포 키메라 항원 수용체(moto-car)
CN115867294A (zh) * 2020-06-04 2023-03-28 凯瑞斯马治疗公司 嵌合抗原受体的新型构建体

Also Published As

Publication number Publication date
US11319358B2 (en) 2022-05-03
JP7032304B2 (ja) 2022-03-08
BR112018001858B1 (pt) 2022-02-08
US20220002375A1 (en) 2022-01-06
CN115747168A (zh) 2023-03-07
US11306133B2 (en) 2022-04-19
CN108025024A (zh) 2018-05-11
US20230279074A1 (en) 2023-09-07
AU2016298229A1 (en) 2018-02-08
AU2016298229B2 (en) 2022-09-08
US20220281947A1 (en) 2022-09-08
ZA201800611B (en) 2023-05-31
RU2018107047A3 (https=) 2020-02-27
US20220002376A1 (en) 2022-01-06
US11407805B2 (en) 2022-08-09
IL297905A (en) 2023-01-01
IL315940A (en) 2024-11-01
US11034749B2 (en) 2021-06-15
IL292507A (en) 2022-06-01
JP2025105634A (ja) 2025-07-10
US11306134B2 (en) 2022-04-19
US20220033467A1 (en) 2022-02-03
AU2022263479B2 (en) 2025-11-06
MX2018001182A (es) 2018-04-20
US20220002377A1 (en) 2022-01-06
US20220033466A1 (en) 2022-02-03
RU2766690C2 (ru) 2022-03-15
CN121896174A (zh) 2026-04-21
JP2022028831A (ja) 2022-02-16
MX393707B (es) 2025-03-24
JP2018521667A (ja) 2018-08-09
US11359002B2 (en) 2022-06-14
RU2018107047A (ru) 2019-08-28
HK1256141A1 (zh) 2019-09-13
EP3328402A1 (en) 2018-06-06
JP7600081B2 (ja) 2024-12-16
US20220033468A1 (en) 2022-02-03
MX2022008288A (es) 2022-08-08
US20180244748A1 (en) 2018-08-30
US20220033465A1 (en) 2022-02-03
JP2023090882A (ja) 2023-06-29
KR20180028533A (ko) 2018-03-16
AU2026200155A1 (en) 2026-01-29
IL292507B2 (en) 2025-03-01
CN108025024B (zh) 2022-11-29
US11325963B2 (en) 2022-05-10
US11498954B2 (en) 2022-11-15
KR102697827B1 (ko) 2024-08-23
CA2992742A1 (en) 2017-02-02
IL256892B (en) 2022-06-01
BR112018001858A2 (en) 2018-09-18
AU2022263479A1 (en) 2022-12-08
US20220041688A1 (en) 2022-02-10
US20260008833A1 (en) 2026-01-08
WO2017019848A1 (en) 2017-02-02
EP3328402A4 (en) 2019-04-03
US11332511B2 (en) 2022-05-17
US20200247870A1 (en) 2020-08-06
IL256892A (en) 2018-03-29
NZ739224A (en) 2025-02-28
IL292507B1 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US11498954B2 (en) Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
US12344843B2 (en) Altering gene expression in cart cells and uses thereof
CA2992742C (en) Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
HK40089233A (zh) 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000